European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact

4th NEEM in Riga: Key messages on prostate cancer treatment issues

Pelvic lymph node dissection and managing pT3 prostate disease were among the topics discussed during the session on prostate cancer treatment.

Fri, 10 Sep 2010
Prostate CancerOncologyNorth Eastern European Meeting NEEMLymph Node Dissection LND

Pelvic lymph node dissection and managing pT3 prostate disease were among the topics discussed during the session on prostate cancer treatment held at the 4th North Eastern European Meeting (NEEM) which opened today in Riga, Latvia.

Goran Ahlgren (Sweden) lectured on lymph node dissection in prostate cancer during the opening session, while Dr. Ejils Vjaters examined managing pT3 prostate disease.

In his lecture, Ahlgren recommended that in cases when the surgeon opts for pelvic lymph node dissection an extended lymphadenectomy would be beneficial.

“Why do need to have lymph node dissection (LND) in prostate cancer? We want to have information about cancer stage and prognosis and potential benefit in cancer cure,” Ahlgren said, adding, however, that limited LND doesn’t provide correct lymph node staging.

Among the key messages Ahlgren‘s lecture were:

  • If a PLND is performed for prostate cancer, extended PLND is recommended* PLND maybe excluded in Gleason score < 6 or 3+4 and PSA <10ng/ml
  • Positive node is prognostic for disease-specific survival
  • PLND may increase cure rate, if < 2-3 positive nodes.
  • If node is positive, still consider to treat the prostate*Treating the prostate may be more important for survival than the LND?

Regarding pT3 prostate disease, Dr. Ejils Vjaters gave the following key messages:

For patients classified as pT3 pN0 with a high risk of local failure after RP due to positive margins (highest impact), capsule rupture, and/or invasion of the seminal vesicles, who present with a PSA level of < 0.1 ng/ml, two options can be offered: -either an immediate radiotherapy to the surgical bed upon recovery of urinary function-or clinical and biological monitoring followed by salvage radiotherapy when the PSA exceeds 0.5 ng ml,

  • Neoadjuvant hormonal therapy before RP does not provide a significant disease-free survival and OS advantage over prostatectomy alone;
  • Adjuvant hormonal therapy following RP shows no survival advantage at 10 years;
  • Adjuvant hormonal therapy following RP: the overall effect estimate for disease-free survival was highly statistically significant in favour of the hormonal therapy arm.

Share this article

Suggested for you

See all
About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer